The impact of pharmacotherapy on sexual function in female patients being treated for idiopathic overactive bladder: a systematic review
- PMID: 38755593
- PMCID: PMC11097459
- DOI: 10.1186/s12905-024-03103-1
The impact of pharmacotherapy on sexual function in female patients being treated for idiopathic overactive bladder: a systematic review
Abstract
Background: Overactive bladder (OAB) is a condition defined by urgency with or without incontinence which disproportionately affects female patients and has a negative impact on sexual enjoyment and avoidance behaviour. Pharmacotherapy can be considered one of the main options for treating OAB. This research set out to determine the impact of pharmacotherapy on sexual function in females with OAB.
Methods: This research used the robust methodology of a systematic review. The clinical question was formulated using the PICO (population, intervention, control, and outcomes) format to include females being treated with pharmacotherapy (anticholinergics or beta-3 adrenergic agonists) for idiopathic OAB with the use of a validated questionnaire assessing self-reported sexual function at baseline and post-treatment. The review incorporated the MEDLINE, PubMed and EMBASE databases. The AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews) appraisal tool was used to guide the review process. Two reviewers worked independently in screening abstracts, deciding on the inclusion of full-texts, data extraction and risk of bias assessment.
Results: In female patients with OAB, pharmacotherapy does seem to offer at least partial improvement in self-reported sexual function outcomes after 12 weeks of therapy. Still, the value of this finding is limited by an overall poor quality of evidence. Patients with a higher degree of bother at baseline stand to benefit the most from treatment when an improvement within this health-related quality of life domain is sought.
Conclusion: This research should form the basis for a well-conducted randomized controlled study to accurately assess sexual function improvements in females being treated with pharmacotherapy for OAB.
Keywords: Female; Overactive bladder; Sexual function.
© 2024. The Author(s).
Conflict of interest statement
All authors of this research declare that no grant from private, public, or not-for-profit sectors was provided. No author has a conflict of interest to declare.
Figures
Similar articles
-
Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD003193. doi: 10.1002/14651858.CD003193.pub4. Cochrane Database Syst Rev. 2012. PMID: 23235594 Free PMC article.
-
Bladder training for treating overactive bladder in adults.Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD013571. doi: 10.1002/14651858.CD013571.pub2. Cochrane Database Syst Rev. 2023. PMID: 37811598 Free PMC article.
-
Botulinum toxin injections for adults with overactive bladder syndrome.Cochrane Database Syst Rev. 2011 Dec 7;(12):CD005493. doi: 10.1002/14651858.CD005493.pub3. Cochrane Database Syst Rev. 2011. PMID: 22161392
-
Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults.Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003193. doi: 10.1002/14651858.CD003193.pub3. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2012 Dec 12;12:CD003193. doi: 10.1002/14651858.CD003193.pub4. PMID: 17054163 Updated.
-
Acupuncture for treating overactive bladder in adults.Cochrane Database Syst Rev. 2022 Sep 23;9(9):CD013519. doi: 10.1002/14651858.CD013519.pub2. Cochrane Database Syst Rev. 2022. PMID: 36148895 Free PMC article.
Cited by
-
Sexual Dysfunction in Patients with Overactive Bladder Syndrome Treated with Botulinum Toxin.J Clin Med. 2024 Oct 1;13(19):5869. doi: 10.3390/jcm13195869. J Clin Med. 2024. PMID: 39407929 Free PMC article.
References
-
- Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony) Eur Urol. 2015;67(3):577–588. doi: 10.1016/j.eururo.2014.02.012. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical